|
The impact of Arsenic trioxide and thalidomideon VEGF A gene expression in AML cell lines
|
M. Mohammadi Kian   , M. Mohammadi  , M. Tavallaie , M. Sadeghi , M. Nikbakht |
|
|
| Keywords: Key words: Arsenic, Thalidomide, Acute Myeloid Leukemia |
|
|
Full-Text [PDF 1060 kb]
(1672 Downloads)
| Abstract (HTML) (31176 Views)
|
Type of Study: Research |
Subject:
Hematology and Oncology
Published: 2019/04/8
|
|
|
|
|
|
|
Full-Text: (4167 Views) |
References:
- Coldman A, Goldie J. A stochastic model for the origin and treatment of tumors containing drug-resistant cells. Bull Math Biol 1986; 48(3-4): 279-92.
- Lapidot T, Sirard C, Vormoor J, Murdoch B, Hoang T, Caceres-Cortes J, et al. A cell initiating humanacute myeloid leukaemia after transplantation into SCID mice. Nature 1994; 367(6464): 645.
- Gora-Tybor J, Blonski JZ, Robak T. Circulating vascular endothelial growth factor (VEGF) and its soluble receptors in patients with chronic lymphocytic leukemia. Eur Cytokine Netw 2005; 16(1): 41-6.
- Hata AN, Breyer RM. Pharmacology and signaling of prostaglandin receptors: multiple roles in inflammation and immune modulation. Pharmacol
Ther 2004; 103(2): 147-66 .
- Hayashibara T, Yamada Y, Miyanishi T, Mori H, Joh T, Maeda T, et al. Vascular endothelial growth factor and cellular chemotaxis: a possible autocrine pathway in adult T-cell leukemia cell invasion. Clin Cancer Res 2001; 7(9): 2719-26.
- Holmes K, Roberts OL, Thomas AM, Cross MJ. Vascular endothelial growth factor receptor-2: structure, function, intracellular signalling and therapeutic inhibition. Cell Signal 2007; 19(10): 2003-12.
- Hu X, Mendoza FJ, Sun J, Banerji V, Johnston JB, Gibson SB. Lysophosphatidic acid (LPA) induces the expression of VEGF leading to protection against apoptosis in B-cell derived malignancies. Cell Signal 2008; 20(6): 1198-208.
- Miller WH, Schipper HM, Lee JS, Singer J, Waxman S. Mechanisms of action of arsenic trioxide. Cancer Research 2002; 62(14): 3893-903.
- Mandegary A, Hosseini R, Ghaffari S, Alimoghaddam K, Rostami S, Ghavamzadeh A, et al. The expression of p38, ERK1 and Bax proteins has increased during the treatment of newly diagnosed acute promyelocytic leukemia with arsenic trioxide. Ann Oncol 2010; 21(9): 1884-90.
- Mohammadi Kian M, Mohammadi S, Tavallaei M, Chahardouli B, Rostami S, Zahedpanah M, et al. Inhibitory Effects of Arsenic Trioxide and Thalidomide on Angiogenesis and Vascular Endothelial Growth Factor Expression in Leukemia Cells. Asian Pac J Cancer Prev 2018; 19(4): 1127-1134.
- Haghi A, Mohammadi S, Heshmati M, Ghavamzadeh A, Nikbakht M. Anti-vascular endothelial growth factor effects of sorafenib and arsenic trioxide in acute myeloid leukemia cell lines. Asian Pac J Cancer Prev 2017; 18(6): 1655-61.
- Salemi M, Ghavamzadeh A, Nikbakht M. Anti-Vascular Endothelial Growth Factor Targeting by Curcumin and Thalidomide in Acute Myeloid Leukemia Cells. Asian Pac J Cancer Prev 2017; 18(11): 3055-61.
- Rao J, Xu D-R, Zheng F-M, Long Z-J, Huang S-S, Wu X, et al. Curcumin reduces expression of Bcl-2, leading to apoptosis in daunorubicin-insensitive CD34+ acute myeloid leukemia cell lines and primary sorted CD34+ acute myeloid leukemia cells. J Transl Med 2011; 9(1): 71.
- Döhner H, Weisdorf DJ, Bloomfield CD. Acute
Myeloid Leukemia. N Engl J Med 2015; 373(12): 1136-52 .
- Gusenbauer S, Zanucco E, Knyazev P, Ullrich A. Erk2 but not Erk1 regulates crosstalk between Met and EGFR in squamous cell carcinoma cell lines. Mol Cancer 2015; 14(1): 54.
- Carter-Cooper B, Sadowska M, Wonodi O, Lapidus RG, Levis M, Sausville EA. Synergistic Antileukemic Effect Of Sequential Administration Of Dichloroacetate (DCA) Combined With Arsenic Trioxide (ATO) In Primary Blasts From Patients With Acute Myeloid Leukemia (AML) and FLT3-ITD AML Cell Lines. Blood 2013; 122: 3955.
- Katoh O, Tauchi H, Kawaishi K, Kimura A, Satow Y. Expression of the vascular endothelial growth factor (VEGF) receptor gene, KDR, in hematopoietic cells and inhibitory effect of VEGF on apoptotic cell death caused by ionizing radiation. Cancer Res 1995; 55(23): 5687-92.
- Roboz GJ, Dias S, Lam G, Lane WJ, Soignet SL, Warrell RP, et al. Arsenic trioxide induces dose-and time-dependent apoptosis of endothelium and may exert an antileukemic effect via inhibition of angiogenesis. Blood 2000; 96(4): 1525-30.
- D'Amato RJ, Loughnan MS, Flynn E, Folkman J. Thalidomide is an inhibitor of angiogenesis. Proc Natl Acad Sci U S A 1994; 91(9): 4082-5.
- KENYON BM, Browne F, D'amato RJ. Effects of thalidomide and related metabolites in a mouse corneal model of neovascularization. Exp Eye Res 1997; 64(6): 971-8.
- Eisen T, Boshoff C, Vaughan M, Pyle L, Smith I, Johnston S, et al. Continuous low dose Thalidomide: a phase II study in advanced melanoma, renal cell, ovarianand breast cancer. Br J Cancer 2000; 82(4): 812-7.
- Dahut WL, Gulley JL, Arlen PM, Liu Y, Fedenko KM, Steinberg SM, et al. Randomized phase II trial of docetaxel plus thalidomide in androgen-independent prostate cancer. J Clin Oncol 2004; 22(13): 2532-9.
- Long G, Vredenburgh J, Rizzieri D. Pilot trial of thalidomide post-autologous peripheral blood progenitor cell transplantation (PBPC) in patients with metastatic breast cancer. Proc Am Soc Clin Oncol; 1998.
- Marx G, Levi J, Bell D, Boyle F, McCowatt S, Monk R, et al. A phase I/II trial of thalidomide as an antiangiogenic agent in the treatment of advanced cancer. Proc Annu Meet Am Soc Clin Oncol; 1999.
- Steins M, Bieker R, Padro T, Kessler T, Kienast J, Berdel W, et al. Thalidomide for the treatment of acute myeloid leukemia. Leuk Lymphoma 2003; 44(9): 1489-93.
- Chen GQ, Zhu J, Shi XG, Ni J, Zhong H, Si G, et al. In vitro studies on cellular and molecular mechanisms of arsenic trioxide (As2O3) in the treatment of acute promyelocytic leukemia: As2O3 induces NB4 cell apoptosis with downregulation of Bcl-2 expression and modulation of PML-RAR alpha/PML proteins. Blood 1996; 88(3): 1052-61.
- Yang MH, Zang YS, Huang H, Chen K, Li B, Sun GY, et al. Arsenic trioxide exerts anti-lung cancer activity by inhibiting angiogenesis. Curr Cancer Drug Targets 2014; 14(6): 557-66.
|
Sci J Iran Blood Transfus Organ 2019; 16(1): 44-56
|
The impact of Arsenic trioxide and thalidomide
on VEGF A gene expression in AML cell lines
Mohammadi Kian M.1, Mohammadi S.2, Tavallaie M.1, Sadeghi M.1, Nikbakht M.2
1Human Genetics Research Center, Baqiyatallah University of Medical Sciences, Tehran, Iran
2Hematology, Oncology and Stem Cell Transplantation Research Center, Tehran University of Medical Sciences, Shariati Hospital, Tehran, Iran
Abstract
Background and Objectives
Arsenic trioxide has anti-cancer effects on a wide range of cancers, mainly by inducing apoptosis in cancerous cells. Thalidomide is an inhibitor of angiogenesis. The main purpose of this study was to investigate the combined effect of arsenic trioxide and thalidomide on the expression level of VEGF A gene.
Materials and Methods
In this experimental study, MTT test was used to investigate the effect of arsenic trioxide and thalidomide both in isolation as combined on cell viability of KG-1 and U937 cells at different times and different doses. Cell apoptosis was assessed by flow cytometry. The level of mRNA expression of VEGF A gene was assessed by Real Time PCR. Student-t, ANOVA and SPSS-17 software were used for data analysis.
Results
The selective doses of arsenic trioxide in the KG-1 and U937 cell lines were 1.618 μM and 1 μM, respectively. The selective doses of thalidomide in the KG-1 and U937 cell lines were 80 μM and 60 μM, respectively. Combination of arsenic trioxide and thalidomide had a significant effect on both cell lines. On the other hand, the expression of the VEGF A gene significantly decreased.
Conclusions
The present study showed that the expression of VEGF A gene in 1-KG and U937 cell lines decreased and the combination effect of arsenic trioxide and thalidomide on the cells induced apoptosis. To confirm these results further investigation is required on the protein level.
Key words: Arsenic, Thalidomide , Acute Myeloid Leukemia
Received: 30 Apr 2018
Accepted: 23 Sep 2018
Correspondence: Nikbakht M., PhD in Medical Biotechnology. Hematology, Oncology and Stem Cell Transplantation Research Center, Tehran University of Medical Sciences, Shariati Hospital.
Postal Code: 1411713131, Tehran, Iran. Tel: (+9821) 84902635; Fax: (+9821) 84902635
E-mail:
|
m-nikbakht@sina.tums.ac.ir
|
|
|
| Send email to the article author |
|
|
|
| Add your comments about this article |
|
|
|
|
Mohammadi Kian M, Mohammadi M, Tavallaie M, Sadeghi M, Nikbakht M. The impact of Arsenic trioxide and thalidomideon VEGF A gene expression in AML cell lines. Sci J Iran Blood Transfus Organ 2019; 16 (1) :44-56 URL: http://bloodjournal.ir/article-1-1198-en.html
|
.jpg)
.png)
